KYTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
39.6M
-4.4%
41.4M
+5.3%
39.3M
+1.4%
38.7M
-12.8%
44.4M
R&D
24.8M
-17.6%
30.1M
+0.2%
30.0M
-1.5%
30.5M
-15.0%
35.8M
SG&A
14.8M
+30.8%
11.3M
+21.9%
9.3M
+12.1%
8.3M
-3.8%
8.6M
Operating Income
-39556000
+4.4%
-41367000
-5.3%
-39282000
-1.4%
-38727000
+12.8%
-44410000
EBITDA
-39122000
+4.6%
-41016000
-5.4%
-38914000
-1.6%
-38312000
+12.7%
-43895000
Net Income
-38319000
+3.5%
-39728000
-5.1%
-37804000
-2.8%
-36787000
+12.6%
-42081000
EPS (Basic)
$-0.63
+4.5%
$-0.66
+17.5%
$-0.80
+5.9%
$-0.85
+12.4%
$-0.97
EPS (Diluted)
$-0.63
+4.5%
$-0.66
+17.5%
$-0.80
+5.9%
$-0.85
+12.4%
$-0.97
Shares (Diluted)
60.9M
+0.8%
60.4M
+28.1%
47.2M
+8.7%
43.4M
+0.4%
43.2M
Kyverna Therapeutics (KYTX) โ€” Financials